Due to COVID-19, new study enrollment is being assessed on a case by case basis. If you have any questions please call our central phone number at 616-391-1230.

Rare Protocols

Breast

Protocol SWOG S1706
Cancer Type: Inflammatory Breast Cancer

A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer

Please check out the rare protocol list to locate other studies within this disease site.

Endocrine/Neuroendocrine

Protocol Alliance A021804
Cancer Type: ADVANCED PHEOCHROMOCYTOMA AND PARAGANGLIOMA

A PROSPECTIVE, MULTI-INSTITUTIONAL PHASE II TRIAL EVALUATING TEMOZOLOMIDE VS. TEMOZOLOMIDE AND OLAPARIB FOR ADVANCED PHEOCHROMOCYTOMA AND PARAGANGLIOMA

Please check out the rare protocol list to locate other studies within this disease site.

Gastrointestinal

Protocol SWOG S1922
Cancer Type: Small bowel Adenocarcinoma

Randomized Phase II Selection Study of Ramucirumab and Paclitaxel versus FOLFIRI in Refractory Small Bowel Adenocarcinoma

Please check out the rare protocol list to locate other studies within this disease site.

Genitourinary

Protocol Alliance A031702
Cancer Type: rare genitourinary tumors

Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors

Please check out the rare protocol list to locate other studies within this disease site.

Head and Neck

Protocol SWOG S1701
Cancer Type: Thymic Carcinoma

A Randomized Phase II Trial of Carboplatin-Paclitaxel with or Without Ramucirumab in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma

Please check out the rare protocol list to locate other studies within this disease site.

Protocol NRG HN007
Cancer Type: NASOPHARYNGEAL CARCINOMA

AN OPEN-LABEL, PHASE III STUDY OF PLATINUM-GEMCITABINE WITH OR WITHOUT NIVOLUMAB IN THE FIRST-LINE TREATMENT OF RECURRENT OR METASTATIC NASOPHARYNGEAL CARCINOMA

Protocol NRG HN001
Cancer Type: Nasopharyngeal Carcinoma

Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)

Please check out the rare protocol list to locate other studies within this disease site.

Protocol EA3163
Cancer Type: Nasal and Paranasal Sinus Squamous Cell Carcinoma

Phase II Randomized Trial of Neo-Adjuvant Chemo f/b Surgery and Post-Op Radiation vs Surgery and Post-Op Radiation for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma (NPNSCC)

Protocol NRG HN004
Cancer Type: Locoregionally Advanced Head and Neck Cancer

Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Locoregionally Advanced Head and Neck Cancer with a Contraindication to Cisplatin

Please check out the rare protocol list to locate other studies within this disease site.

Lung

Protocol NRG LU006
Cancer Type: MALIGNANT PLEURAL MESOTHELIOMA

PHASE III RANDOMIZED TRIAL OF PLEURECTOMY/DECORTICATION PLUS
CHEMOTHERAPY WITH ORWITHOUT ADJUVANT HEMITHORACIC
INTENSITY-MODULATED PLEURAL RADIATION THERAPY (IMPRINT)
FOR MALIGNANT PLEURAL MESOTHELIOMA (MPM)

Please check out the rare protocol list to locate other studies within this disease site.

Lymphoma

Protocol E4412
Cancer Type: Refractory Hodgkin Lymphoma

Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma

Please check out the rare protocol list to locate other studies within this disease site.

Rare

Protocol Alliance A091902
Cancer Type: ANGIOSARCOMA

A MULTICENTER PHASE II TRIAL OF PACLITAXEL WITH AND WITHOUT NIVOLUMAB IN TAXANE NAÏVE, AND NIVOLUMAB AND CABOZANTINIB IN TAXANE PRETREATED SUBJECTS WITH ANGIOSARCOMA

Please check out the rare protocol list to locate other studies within this disease site.

Protocol Alliance A021804
Cancer Type: ADVANCED PHEOCHROMOCYTOMA AND PARAGANGLIOMA

A PROSPECTIVE, MULTI-INSTITUTIONAL PHASE II TRIAL EVALUATING TEMOZOLOMIDE VS. TEMOZOLOMIDE AND OLAPARIB FOR ADVANCED PHEOCHROMOCYTOMA AND PARAGANGLIOMA

Please check out the rare protocol list to locate other studies within this disease site.

Protocol SWOG S1706
Cancer Type: Inflammatory Breast Cancer

A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer

Please check out the rare protocol list to locate other studies within this disease site.

Protocol SWOG S1922
Cancer Type: Small bowel Adenocarcinoma

Randomized Phase II Selection Study of Ramucirumab and Paclitaxel versus FOLFIRI in Refractory Small Bowel Adenocarcinoma

Please check out the rare protocol list to locate other studies within this disease site.

Protocol Alliance A031702
Cancer Type: rare genitourinary tumors

Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors

Please check out the rare protocol list to locate other studies within this disease site.

Protocol EA3163
Cancer Type: Nasal and Paranasal Sinus Squamous Cell Carcinoma

Phase II Randomized Trial of Neo-Adjuvant Chemo f/b Surgery and Post-Op Radiation vs Surgery and Post-Op Radiation for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma (NPNSCC)

Protocol SWOG S1701
Cancer Type: Thymic Carcinoma

A Randomized Phase II Trial of Carboplatin-Paclitaxel with or Without Ramucirumab in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma

Protocol NRG HN001
Cancer Type: Nasopharyngeal Carcinoma

Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)

Protocol NRG HN004
Cancer Type: Locoregionally Advanced Head and Neck Cancer

Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Locoregionally Advanced Head and Neck Cancer with a Contraindication to Cisplatin

Protocol NRG HN007
Cancer Type: NASOPHARYNGEAL CARCINOMA

AN OPEN-LABEL, PHASE III STUDY OF PLATINUM-GEMCITABINE WITH OR WITHOUT NIVOLUMAB IN THE FIRST-LINE TREATMENT OF RECURRENT OR METASTATIC NASOPHARYNGEAL CARCINOMA

Please check out the rare protocol list to locate other studies within this disease site.

Protocol NRG LU006
Cancer Type: MALIGNANT PLEURAL MESOTHELIOMA

PHASE III RANDOMIZED TRIAL OF PLEURECTOMY/DECORTICATION PLUS
CHEMOTHERAPY WITH ORWITHOUT ADJUVANT HEMITHORACIC
INTENSITY-MODULATED PLEURAL RADIATION THERAPY (IMPRINT)
FOR MALIGNANT PLEURAL MESOTHELIOMA (MPM)

Please check out the rare protocol list to locate other studies within this disease site.

Protocol E4412
Cancer Type: Refractory Hodgkin Lymphoma

Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma

Please check out the rare protocol list to locate other studies within this disease site.

Protocol EA6174
Cancer Type: Merkel Cell Carcinoma

A Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma

Please check out the rare protocol list to locate other studies within this disease site.

Sarcoma

Protocol Alliance A091902
Cancer Type: ANGIOSARCOMA

A MULTICENTER PHASE II TRIAL OF PACLITAXEL WITH AND WITHOUT NIVOLUMAB IN TAXANE NAÏVE, AND NIVOLUMAB AND CABOZANTINIB IN TAXANE PRETREATED SUBJECTS WITH ANGIOSARCOMA

Please check out the rare protocol list to locate other studies within this disease site.

Skin

Protocol EA6174
Cancer Type: Merkel Cell Carcinoma

A Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma

Please check out the rare protocol list to locate other studies within this disease site.

Cancer clinical trials are research studies for developing better ways of detecting, treating, and eventually preventing cancer. By taking part in a clinical trial, you are among the first to receive new research treatments before they are widely available. Your participation in a clinical trial will influence the future direction of cancer care.

If you are interested in participating in a clinical trial, consult with your physician. Please note: clinical trials are not risk free. Patients must explore the options that are best for their individuals needs with the help of their physician.